VRTX - Vertex Pharmaceuticals Inc

VRTX

$485.22 21.78 (-4.30%)

After Hours: $485.22 +0.00 (+0.00%)

Last updated: Oct 13, 2026 22:15

52-Week Range

$485.22

$403.16 $485.22 $560.25

Fundamentals Overview

Vertex Pharmaceuticals Inc is in the middle of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/E 29.5 PEG 2.5 P/B 6.23 P/S 10.31

Profitability

ROE 23.31% Net margin 35%

Risk (Beta)

0.28 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 55% confidence Risk: Lower Volatility — Beta 0.28. Diversify and only invest what you can afford to lose.

Pressures (Sell):

PEG 2.5 · P/S 10.31 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$128.50B

P/E (TTM)

29.46

EPS (TTM)

N/A

Dividend Yield

N/A

52-Week Range

$403.16 - $560.25

Volume vs Avg

1.15x

115% of avg (Above)

Beta

0.28

About

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute...

Sector: Healthcare

Headquarters: US

Website: www.vrtx.com

Beta: 0.28 (Less volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	29.46
PEG (TTM)	2.5
P/B (TTM)	6.23
P/S (TTM)	10.31
Profitability
ROE (TTM)	23.31%
ROA (TTM)	16.88%
Revenue growth (YoY)	N/A
Net margin (TTM)	35%
Gross margin (TTM)	86%
Operating margin (TTM)	37.95%
Debt to equity (TTM)	0

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for VRTX.

Loading analyst coverage...

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.